BR-007

N/A

Report date: 2025/06/18 14:58:48

NME

Base Information

Drug NameBR-007

Drug Alias NameSodium (1-hydroxy-4-(((2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethoxy)carbonyl)amino)butane-1,1-diyl)bis(hydrogen phosphonate)BR-007

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAnti-TGF-β

TargetsTransforming growth factor beta

Therapy Area/IndicationsCamurati-Engelmann Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesXiyuan Anjian Pharmaceutical (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesXiyuan Anjian Pharmaceutical (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsCamurati-Engelmann Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A